COVID-19 Prevention Efficacy of Oral Nosode Therapy Investigated

Strategic Insights -

Researchers at the Department of Research, led by Gitanjali Talele, have published a study investigating the safety, efficacy, and immunogenicity of an oral homeopathic SARS-CoV-2 nosode, BiosimCovex, in preventing COVID-19 infection. The phase III, multicentre, randomized, double-blind, placebo-controlled trial involved 2671 unvaccinated participants from 13 sites in India. Participants received either six doses of BiosimCovex or a placebo over three days. The study aimed to assess the efficacy of BiosimCovex in preventing COVID-19 infection and its immunogenicity. The research found that the effectiveness of BiosimCovex was highest at day 45 in females and in the 18- to 40-year-old age group.

Key Takeaways:

  • The study involved 2671 unvaccinated participants from 13 sites in India, who received either six doses of BiosimCovex or a placebo over three days.
  • The study found that the maximum efficacy of BiosimCovex occurred at day 45, with an overall efficacy of 50.06%, 71.88% in individuals aged 18-40 years, and 61.57% in females.
  • The study reported 23 positive RT-PCR cases per group, with 1.3% in the BiosimCovex group and 2.6% in the placebo group, resulting in a relative risk (RR) of 0.63 at the end of the study over 60 days.
  • Antibody conversion increased over time, with 48.4% becoming antibody positive by day 60 in the treatment group compared to 13.4% in the placebo group.
  • The study concluded that effectiveness was highest at day 45 in females and in the 18- to 40-year-old age group.

Statistics:

  • 2671 participants were enrolled in the study from 13 sites in India.
  • 1781 participants received six doses of BiosimCovex, while 890 participants received a placebo.
  • The study reported 59 positive RT-PCR cases, with 33 cases in the BiosimCovex group and 26 cases in the placebo group.
  • The efficacy of BiosimCovex was 50.06% overall, 71.88% in individuals aged 18-40 years, and 61.57% in females.
  • The relative risk (RR) of COVID-19 infection in the BiosimCovex group was 0.63 compared to the placebo group at the end of the study over 60 days.

Sources:

  • NewsRx. New Findings from Department of Research Describe Advances in COVID-19 [Protection From SARS-CoV-2 Infection With an Oral Nosode (BiosimCovex): A Randomized, Double-Blind, Placebo-Controlled, Phase III Study]. Medical Letter on the CDC & FDA. October 26, 2025; p 115.
  • Protection From SARS-CoV-2 Infection With an Oral Nosode (BiosimCovex): A Randomized, Double-Blind, Placebo-Controlled, Phase III Study. Global Advances in Integrative Medicine and Health, 2025;14:27536130251386048.